Lipocine
LPCN
42 hedge funds and large institutions have $12.4M invested in Lipocine in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 7 closing their positions.
218% more call options, than puts
Call options by funds: $2.51M | Put options by funds: $789K
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
27% more funds holding
Funds holding: 33 → 42 (+9)
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
8% more capital invested
Capital invested by funds: $11.5M → $12.4M (+$908K)
0.21% less ownership
Funds ownership: 0.76% → 0.55% (-0.21%)
Top Buyers
Top Sellers
LPCN Hedge Fund Activity: Q1 2021 in Review
42 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q1 2021, worth a combined $12.4M — up 7.9% from $11.5M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new LPCN positions and 7 closed out — a net gain of 9 holders — while 10 added to existing stakes and 9 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $260K. The largest seller was Kestra Advisory Services, exiting entirely with an estimated $453K sold.
- 42 institutional investors held Lipocine (LPCN) as of Q1 2021, up from 33 in Q4 2020.
- Funds reported $12.4M of Lipocine stock for Q1 2021, up 7.9% quarter-over-quarter.
- 16 funds opened new Lipocine positions in Q1 2021 and 7 closed out, a net change of +9 holders.
- The largest Lipocine buyer in Q1 2021 was Geode Capital Management, an estimated $260K added.
- The largest Lipocine seller in Q1 2021 was Kestra Advisory Services, an estimated $453K sold.
Based on aggregated 13F filings for Q1 2021.